James Caruso - Cellectar Biosciences CEO and President and Director
| CLRB Stock | USD 0.24 0.00 0.000004% |
CEO
Mr. James V. Caruso is President, Chief Executive Officer, Director of Cellectar Biosciences, Inc. He came to Cellectar from Hip Innovation Technology, a medical device company where he was a founder and served as Executive Vice President and Chief Operating Officer from August 2010 to June 2015, and he currently serves on their board. Prior to his time at Hip Innovation Technology, he was Executive Vice President and Chief Commercial Officer of Allos Therapeutics, Inc., an oncology company acquired by Spectrum Pharmaceuticals, from June 2006 to August 2010. He was also Senior Vice President, Sales and Marketing, from June 2002 to May 2005, at Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporationrationration. In addition, Mr. Caruso has held key positions at several wellknown pharmaceutical companies, including Novartis, where he was Vice President of Neuroscience Specialty Sales BASF PharmaceuticalsKnoll, where we was Vice President, Sales, and BristolMyers Squibb Company in several senior roles since 2015.
| Age | 66 |
| Tenure | 10 years |
| Address | 100 Campus Drive, Florham Park, NJ, United States, 07932 |
| Phone | 608 441 8120 |
| Web | https://www.cellectar.com |
James Caruso Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Caruso against Cellectar Biosciences stock is an integral part of due diligence when investing in Cellectar Biosciences. James Caruso insider activity provides valuable insight into whether Cellectar Biosciences is net buyers or sellers over its current business cycle. Note, Cellectar Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cellectar Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Caruso over six months ago Acquisition by James Caruso of 40596 shares of Cellectar Biosciences subject to Rule 16b-3 |
Cellectar Biosciences Management Efficiency
The company has return on total asset (ROA) of (1.66) % which means that it has lost $1.66 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.9667) %, meaning that it created substantial loss on money invested by shareholders. Cellectar Biosciences' management efficiency ratios could be used to measure how well Cellectar Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. At present, Cellectar Biosciences' Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Equity is expected to grow to 3.03, whereas Return On Tangible Assets are forecasted to decline to (2.97). At present, Cellectar Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 1.9 M, whereas Non Currrent Assets Other are forecasted to decline to about 25.5 K.Similar Executives
| Found 2 records | CEO Age | ||
| Teofilo MBA | Pulmatrix | 54 | |
| Christopher Giordano | Tenax Therapeutics | 51 | |
Management Performance
| Return On Equity | -7.97 | ||||
| Return On Asset | -1.66 |
Cellectar Biosciences Leadership Team
Elected by the shareholders, the Cellectar Biosciences' board of directors comprises two types of representatives: Cellectar Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cellectar. The board's role is to monitor Cellectar Biosciences' management team and ensure that shareholders' interests are well served. Cellectar Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cellectar Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, CFO Sec | ||
| Andrei MD, Senior Medical | ||
| Shane Lea, Chief Officer | ||
| Chad CPA, CFO VP | ||
| Darrell Lea, Chief Officer | ||
| Jarrod Longcor, Senior Vice President - Corporate Development and Operations | ||
| James Caruso, CEO and President and Director |
Cellectar Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cellectar Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.97 | ||||
| Return On Asset | -1.66 | ||||
| Current Valuation | (9.9 M) | ||||
| Shares Outstanding | 41.27 M | ||||
| Shares Owned By Insiders | 2.83 % | ||||
| Shares Owned By Institutions | 34.54 % | ||||
| Number Of Shares Shorted | 1.88 M | ||||
| Price To Earning | (1.35) X | ||||
| Price To Book | 6.61 X | ||||
| EBITDA | (38.77 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectar Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. If investors know Cellectar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cellectar Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cellectar Biosciences is measured differently than its book value, which is the value of Cellectar that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectar Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cellectar Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cellectar Biosciences' market value can be influenced by many factors that don't directly affect Cellectar Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cellectar Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectar Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectar Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.